Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular EDEMA

Retina

Volumn 31, Issue 10, 2011, Pages 2058-2064

  Elbendary, Amal M ^a   Shahin, Maha M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Diabetic macular edema; Diclofenac; Intravitreal injection; Triamcinolone acetonide

Indexed keywords

AMCINOL; DICLOFENAC; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA LUTEA; THICKNESS; VISUAL ACUITY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIABETIC RETINOPATHY; DICLOFENAC; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 80055082234     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31822a042a     Document Type: Article

References (36)

1. Massin P, Audren F, Hauchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-224. (Pubitemid 38183217)
2. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927. (Pubitemid 34465226)
3. Benhamou N, Massin P, Haouchine B, et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003;135:246-249. (Pubitemid 36151814)
4. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386-390. (Pubitemid 37100154)
5. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-340. (Pubitemid 38314193)
6. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:270-271.
7. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339. (Pubitemid 41073113)
8. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008;115:1750-1755.
9. Nicholson BP, Schachat AP. A review of clinical trials of anti- VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915-930.
10. Ameri H, Chader GJ, Kim J, et al. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci 2007;48: 5708-5715. (Pubitemid 351260875)
11. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoids macular edema. Am J Ophthalmol 1987;103:479-486. (Pubitemid 17056889)
12. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoids macular edema. Retina 2010;30:s260-s266.
13. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55:108-133.
14. Shen WY, Constable IJ, Chelva E, Rakoczy PE. Inhibition of diclofenac formulated in hyaluronan on angiogenesis in vitro and its intraocular tolerance in rabbit eye. Graefes Arch Clin Exp Ophthalmol 2000;238:273-282. (Pubitemid 30197964)
15. Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 2010;30:509-515.
16. Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol 2011;151:329-332.
17. Lorenz K, Zwiener I,Mirshahi A. Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle. Graefes Arch Clin Exp Ophthalmol 2010;248:1573-1577.
18. Jonas JB, Kreissig I, Saofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61. (Pubitemid 36401766)
19. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-489. (Pubitemid 351447960)
20. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 2007;114: 2162-2167.
21. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.
22. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1449.
23. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy. vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharmaceut Design 2004;10:3331-3347.
24. Hariprasad SM, Callanan D, Gainey S, et al. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharmacol Ther 2007;23:585-590.
25. Shimura M, Nakazawa T, Yasuda K, Nishida K. Diclofenac prevents an early event of macular thickening after cataract surgery in patients with diabetes. J Ocul Pharmacol Ther 2007; 23:284-291. (Pubitemid 46986610)
26. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is down regulated by corticosteroids. Am J Respir Cell Moll Biol 1997;16:398-406. (Pubitemid 127497465)
27. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroids reduces blood-retina barrier breakdown due to laser photocoagulation. Arch Ophthalmol 1992;110: 155-159.
28. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003;217:89-98. (Pubitemid 36237702)
29. Kothari HV, Lee WH, Ku EC. An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium diclofenac. Biochem Biophys Acta 1987;921:502-511. (Pubitemid 17142289)
30. Rabiah PK, Fiscella RG, Tessler HH. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci 1996;37:613-618. (Pubitemid 26077681)
31. Larson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005;139:802-806. (Pubitemid 40614764)
32. Nakajima T, Matsugi T, GotoW, et al. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull 2003;26:1691-1695. (Pubitemid 39663527)
33. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003;19:501-515. (Pubitemid 38030237)
34. Costagliola C, Parmeggiani F, Antinozzi PP, et al. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.005 latanoprost in primary open-angle glaucoma patients. Exp Eye Res 2005;81:610-615. (Pubitemid 41532006)
35. Risk factors associated with age-related nuclear and cortical cataract: a case-control study in the Age-Related Eye Disease Study. Age-Related Eye Disease Study Report Number 5. The Age-Related Eye Disease Study Research Group. Ophthalmology 2001;108:1400-1408.
36. Kim SJ, Adams NA, Toma HS, et al. Safety of intravitreal ketorolac and diclofenac. An electroretinographic and histopathologic study. Retina 2008;28:595-605.